Dr. Lal PathLabs Reports Strong Q1 FY27 Performance with Net Profit Rising 27% YoY to ₹1,705 Million; Revenue Up 19%

Diagnostics major Dr. Lal PathLabs Limited (NSE: LALPATHLAB, BSE: 539523) announced its consolidated unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY27). Driven by sustained expansion in test volumes and operational efficiencies, the healthcare services provider delivered robust year-on-year (YoY) and sequential growth across both top-line and bottom-line metrics.

Key Financial Highlights

Revenue from Operations: Reached ₹7,977 million in Q1 FY27, marking a 19.09% YoY increase compared to ₹6,698 million recorded in Q1 FY26. Sequentially, top-line revenue expanded by 13.52% from ₹7,027 million reported in Q4 FY26.

Total Income: Stood at ₹8,296 million for the quarter, supported by an other income contribution of ₹319 million. This compares to ₹6,979 million in the corresponding quarter of the previous fiscal year.

Profit Before Tax (PBT): Rose 26.28% YoY to ₹2,287 million in Q1 FY27, up from ₹1,811 million in Q1 FY26 and ₹1,601 million in Q4 FY26.

Net Profit After Tax (PAT): Reached ₹1,705 million, reflecting a 27.24% YoY growth over ₹1,340 million reported in Q1 FY26 and a 28.97% sequential increase over ₹1,322 million in Q4 FY26.

Total Comprehensive Income: Stood at ₹1,719 million for the quarter ended June 30, 2026.

Earnings Per Share (EPS): Basic EPS for the quarter rose to ₹10.15 (face value of ₹10/- per share), up from ₹7.94 in Q1 FY26 and ₹7.86 in Q4 FY26. Diluted EPS reached ₹10.13.

Detailed Expense Analysis

Total consolidated expenditure for Q1 FY27 came in at ₹6,009 million, compared to ₹5,168 million in Q1 FY26 and ₹5,666 million in Q4 FY26. Key cost components during the quarter included:

Cost of Materials Consumed: Totaled ₹1,517 million, up from ₹1,289 million in Q1 FY26.

Fees to Collection Centers and Channel Partners: Stood at ₹1,158 million, compared to ₹958 million in Q1 FY26, reflecting network expansion.

Employee Benefits Expense: Reported at ₹1,327 million, up from ₹1,243 million in the corresponding quarter of the previous year.

Depreciation and Amortization: Stood at ₹444 million.

Finance Costs: Recorded at ₹63 million.

Other Expenses: Totaled ₹1,500 million, compared to ₹1,285 million in Q1 FY26.

Tax Expense & Shareholder Returns

Total tax expense for the quarter stood at ₹582 million, comprising current tax of ₹597 million and a deferred tax credit of ₹15 million.

Out of the total net profit of ₹1,705 million, ₹1,695 million was attributable to owners of the company, while non-controlling interests accounted for ₹10 million. Total comprehensive income attributable to the owners of the company stood at ₹1,709 million.

The company's paid-up equity share capital remained at ₹1,676 million (face value ₹10 per share) as of June 30, 2026.

Shares of Dr. Lal Path Labs Ltd. was last trading in BSE at Rs. 1686.70 as compared to the previous close of Rs. 1699.65. The total number of shares traded during the day was 10677 in over 1183 trades.

The stock hit an intraday high of Rs. 1699.65 and intraday low of 1669.70. The net turnover during the day was Rs. 17947456.00.

Source : Equity Bulls

Keywords

DrLalPathLabs INE600L01024 Q1FY27 Q1FY2027 ResultUpdate